RT Journal Article
SR Electronic
T1 Role of alendronate and risedronate in preventing and treating osteoporosis
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 945
OP 951
VO 68
IS 11
A1 Margaret L. Peters
A1 Mandy Leonard
A1 Angelo A. Licata
YR 2001
UL http://www.ccjm.org/content/68/11/945.abstract
AB Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy. Alendronate, however, can be given as a once-weekly dose, whereas risedronate is not yet available in this dosage form. On the other hand, alendronate is not approved for preventing glucocorticoid-induced osteoporosis, whereas risedronate carries this indication.